Regulation of angiotensin-converting enzyme production by nicotine in human endothelial cells

被引:19
作者
Saijonmaa, O
Nyman, T
Fyhrquist, F
机构
[1] Univ Helsinki, Cent Hosp, Minerva Inst Med Res, Helsinki, Finland
[2] Univ Helsinki, Cent Hosp, Dept Internal Med, Helsinki, Finland
来源
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY | 2005年 / 289卷 / 05期
关键词
cardiovascular disease; protein kinase C; renin-angiotensin system; vascular;
D O I
10.1152/ajpheart.01238.2004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nicotine, a component of cigarette smoke, has been implicated in the pathogenesis of cardiovascular disease. We examined whether nicotine regulates angiotensin- converting enzyme ( ACE), an enzyme that plays an important role in the pathophysiology of atherosclerosis and hypertension. Human umbilical cord vein endothelial cells were treated with nicotine ( 0.1 - 1 mu M) alone or in combination with vascular endothelial growth factor ( VEGF; 0.5 nM) or GF- 109203X ( GFX; 2.5 mu M). The amount of ACE in intact endothelial cells was measured by an inhibitor binding assay method, and ACE mRNA levels were quantified using LightCycler technology. Phosphorylated PKC levels were measured by Western immunoblotting. Nicotine did not modulate basal ACE production but significantly potentiated VEGF- induced ACE upregulation. Treatment of endothelial cells with the PKC inhibitor GFX totally blocked VEGF- and nicotine- induced ACE upregulation. VEGF induced PKC phosphorylation, which was potentiated by cotreatment with nicotine. We conclude that nicotine significantly potentiated VEGF- induced ACE upregulation. This effect was probably mediated by PKC phosphorylation. The interaction of nicotine with VEGF in ACE induction may contribute to the pathogenesis of smoking- related cardiovascular disease.
引用
收藏
页码:H2000 / H2004
页数:5
相关论文
共 50 条
  • [21] Activation of the brain angiotensin system by in vivo human angiotensin-converting enzyme gene transfer in rats
    Nakamura, S
    Moriguchi, A
    Morishita, R
    Yamada, K
    Nishii, T
    Tomita, N
    Ohishi, M
    Kaneda, Y
    Higaki, J
    Ogihara, T
    HYPERTENSION, 1999, 34 (02) : 302 - 308
  • [22] The Evolution of Renin-Angiotensin Blockade: Angiotensin-Converting Enzyme Inhibitors as the Starting Point
    Sica, Domenic A.
    CURRENT HYPERTENSION REPORTS, 2010, 12 (02) : 67 - 73
  • [23] Antisense oligodeoxynucleotide inhibition of vascular angiotensin-converting enzyme expression attenuates neointimal formation - Evidence for tissue angiotensin-converting enzyme function
    Morishita, R
    Gibbons, GH
    Tomita, N
    Zhang, LN
    Kaneda, Y
    Ogihara, T
    Dzau, VJ
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2000, 20 (04) : 915 - 922
  • [24] Regulation of Angiotensin-Converting Enzyme 2: A Potential Target to Prevent COVID-19?
    Hu, Yue
    Liu, Lihuan
    Lu, Xifeng
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [25] Angiotensin-converting enzyme inhibition: a landmark advance in treatment for cardiovascular diseases
    Borer, Jeffrey S.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2007, 9 (0E) : E2 - E9
  • [26] Regulation of the angiotensin-converting enzyme activity by a time-course hypoxia in the carotid body
    Lam, SY
    Fung, ML
    Leung, PS
    JOURNAL OF APPLIED PHYSIOLOGY, 2004, 96 (02) : 809 - 813
  • [27] NON-ANGIOTENSIN EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS
    SUNMAN, W
    SEVER, PS
    CLINICAL SCIENCE, 1993, 85 (06) : 661 - 670
  • [28] Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase
    Miyazaki, Mizuo
    Takai, Shinji
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 100 (05) : 391 - 397
  • [29] Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for the Prevention of Migraines
    Gales, Barry J.
    Bailey, Emilee K.
    Reed, Ashley N.
    Gales, Mark A.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (02) : 360 - 366
  • [30] Angiotensin-converting enzyme inhibition by perindopril in cardiovascular disease
    Simoons, Maarten L.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2009, 11 (0E) : E4 - E8